CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 401 enrolled
Drug / intervention
Control Condition +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04114669
NCT04114669N/ACompleted

Behavioral Economics Trial To Enhance Regulation of Blood Pressure

NYU Langone Health·interventional·Posted Oct 3, 2019·Updated May 27, 2026

In Brief

A clinical study evaluating Control Condition and Regret Lottery for High Blood Pressure. Completed, enrolled 401 participants across 1 site.

Detailed Summary

BETTER-BP (Behavioral Economics Trial To Enhance Regulation of Blood Pressure) is a phase II, single-center, prospective, pragmatic randomized clinical trial within the New York City Health and Hospitals (NYC-H+H) system and NYU Langone Family Health Centers. The trial will recruit from 3 NYC-H+H ambulatory clinics as well as NYU Langone Family Health Centers, and will use a lottery incentive program to promote adherence to antihypertensive medication that will be delivered via smartphone for 6 months. The trial will randomize 435 patients with hypertension determined to have poor adherence (\<80% adherence with antihypertensive medication), in a 2:1 (intervention:control) ratio. Baseline enrollment will occur over 36 months with an expected 12 months follow-up per participant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 3, 2019
Enrollment StartJul 14, 2020
Primary CompletionMay 12, 2025
Study CompletionSep 12, 2025
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 6.7 years ago

Interventions

Control Conditionbehavioral

3 in-person study visits, approximately one hour each. These will take place at baseline, 6 months, and 12 months.

Regret Lotterybehavioral

Delivered by the Way to Health platform, installed on a smartphone and communicates with participants via text message.Participants are eligible to receive a potential cash reward if they are adherent with their antihypertensive medication the day before, which is monitored via electronic monitoring device (EMD) from AdhereTech. Each participant is assigned a 2-digit number for the trial, and each day the Way to Health platform randomly generates a 2-digit number. Participants will receive a prize if both digits match (1 in 100 chance) and will receive a prize of lesser value if one digit matches (18 in 100 chance). If they are not adherent with their medication, but would have won if they were adherent, they receive a text message that they would have won ("regret" component).